Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Inflammatory and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for IL-1F10 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IL-1F10 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View IL1F10 Products |
| Gene Delivery | IL-1F10 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View IL1F10 Products |
| Benchmark Ab | Anti-IL-1F10 (Sequence of Clinical Benchmarks) Recombinant positive control. |
View IL1F10 Products |
| Validator | IL-1F10 siRNA Set For knockdown verification. |
View IL1F10 Products |
| Related Target A | IL-36R (IL1RL2) Primary receptor mediating IL-1F10/IL-38 anti-inflammatory signaling. |
View IL36R Products |
| Related Target B | IL-1RAP Co-receptor involved in the tripartite signaling complex. |
View IL1RAP Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse evaluation | Human, Mouse, and Cynomolgus ortholog proteins available with >95% purity |
| Subfamily counter screening (IL-1 family specificity) | Homolog panel proteins (IL-1Ra, IL-36Ra) strictly verified by mass spectrometry |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live IL-1F10 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of the IL-1 family member IL-1F10 (IL-38) is emerging as a novel node in both chronic inflammatory diseases and oncology. Acting as an antagonist of the IL-36 pathway and interacting with IL-1R6 (IL-36R) and IL-1RAP, IL-1F10 exerts natural immunosuppressive functions. In autoimmune contexts, recombinant IL-1F10 or agonist modalities represent a strategy to suppress aberrant IL-36-driven inflammation. Conversely, in the tumor microenvironment, where IL-1F10 can contribute to immune evasion, neutralizing monoclonal antibodies represent a promising immuno-oncology strategy.
The race for IL-1F10 therapeutics is intensifying, with major players shifting focus from traditional mAbs to recombinant fusion proteins and bispecific formats. As first-generation therapies reach the clinic, the next wave of R&D is targeting precision modulation of the IL-1RAP/IL-36R signaling axis to optimize efficacy and avoid systemic off-target effects.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Recombinant Protein (Fc-Fusion) | Preclinical / Academic Consortia | Psoriasis, Rheumatoid Arthritis | Binding kinetics to IL-36R/IL-1RAP (Need high-purity monomeric and dimeric ECDs) |
| Neutralizing mAb | Biotech Startups | Solid Tumors (Immune Evasion) | Epitope mapping and cross-species reactivity (Need Cynomolgus and Mouse orthologs) |
| Bispecific Antibodies | Global Biopharma | Systemic Lupus Erythematosus (SLE) | Simultaneous binding assays (Need target panels with validated sequence integrity) |